Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Seres Therapeutics (MCRB) EBT Margin: 2016-2025

Historic EBT Margin for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to -6,227.64%.

  • Seres Therapeutics' EBT Margin was N/A to -6,227.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -94,588.79%, marking a year-over-year change of. This contributed to the annual value of -150.61% for FY2023, which is 241499.00% up from last year.
  • Latest data reveals that Seres Therapeutics reported EBT Margin of -6,227.64% as of Q3 2025, which was down 215.20% from 5,405.83% recorded in Q1 2024.
  • Over the past 5 years, Seres Therapeutics' EBT Margin peaked at 5,405.83% during Q1 2024, and registered a low of -54,770.31% during Q4 2023.
  • Its 3-year average for EBT Margin is -13,800.21%, with a median of -9,890.27% in 2023.
  • In the last 5 years, Seres Therapeutics' EBT Margin tumbled by 5,454,498bps in 2023 and then skyrocketed by 1,910,008bps in 2024.
  • Over the past 5 years, Seres Therapeutics' EBT Margin (Quarterly) stood at -688.06% in 2021, then skyrocketed by 46,273bps to -225.33% in 2022, then tumbled by 5,454,498bps to -54,770.31% in 2023, then skyrocketed by 1,910,008bps to 5,405.83% in 2024, then reached -6,227.64% in 2025.
  • Its EBT Margin stands at -6,227.64% for Q3 2025, versus 5,405.83% for Q1 2024 and -54,770.31% for Q4 2023.